Rajesh Ramanathan1, Amy L Olex2, Mikhail Dozmorov2, Harry D Bear1, Leopoldo Jose Fernandez1, Kazuaki Takabe3. 1. Division of Surgical Oncology, Massey Cancer Center, Virginia Commonwealth University Medical Center, 1200 E. Broad St, Richmond VA 23298. 2. Virginia Commonwealth University C. Kenneth and Diane Wright Center for Clinical and Translational Research, 1200 E. Clay St, Richmond VA 23298. 3. Breast Surgery Service, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo NY 14263.
Abstract
PURPOSE: Angiogenesis is one of the hallmarks of cancer and is essential for cancer progression and metastasis. However, clinical trials with vascular endothelial growth factor (VEGF) pathway inhibitors have failed to show overall survival benefit in breast cancer. Targeted therapy against the angiopoietin pathway, a downstream angiogenesis cascade, could be effective in breast cancer. This study investigates the association of angiopoietin pathway gene expression with breast cancer survival using a "big data" approach employing RNA sequencing data from The Cancer Genome Atlas (TCGA). METHODS: A total of 888 patients with adequate gene expression, disease-free survival (DFS), and overall survival (OS) data were selected for analysis. DFS and OS were calculated for patients with high and low expression of angiopoietin and VEGF pathway genes using TCGA data. Gene-specific thresholds to dichotomize patients into high and low expression were determined and survival plots were generated. RESULTS: The TCGA cohort was representative of national breast cancer patients with respect to stage, pathology, and survival. High Ang2 gene expression was associated with not only decreased DFS (p = 0.05), but also decreased OS (p < 0.05). High co-expression of Ang2 and its receptor Tie2 was associated with both decreased DFS and OS (p < 0.05). There was strong correlation between angiopoietin and VEGF pathway genes. While high expression of VEGFA alone was not associated with survival, high co-expression with Ang2 was associated with decreased OS. CONCLUSIONS: This study validates TCGA as a representative database providing genomic data and survival outcomes in breast cancer. Our TCGA data support the angiopoietin pathway as a key mediator in the pathologic angiogenic switch in breast cancer.
PURPOSE: Angiogenesis is one of the hallmarks of cancer and is essential for cancer progression and metastasis. However, clinical trials with vascular endothelial growth factor (VEGF) pathway inhibitors have failed to show overall survival benefit in breast cancer. Targeted therapy against the angiopoietin pathway, a downstream angiogenesis cascade, could be effective in breast cancer. This study investigates the association of angiopoietin pathway gene expression with breast cancer survival using a "big data" approach employing RNA sequencing data from The Cancer Genome Atlas (TCGA). METHODS: A total of 888 patients with adequate gene expression, disease-free survival (DFS), and overall survival (OS) data were selected for analysis. DFS and OS were calculated for patients with high and low expression of angiopoietin and VEGF pathway genes using TCGA data. Gene-specific thresholds to dichotomize patients into high and low expression were determined and survival plots were generated. RESULTS: The TCGA cohort was representative of national breast cancerpatients with respect to stage, pathology, and survival. High Ang2 gene expression was associated with not only decreased DFS (p = 0.05), but also decreased OS (p < 0.05). High co-expression of Ang2 and its receptor Tie2 was associated with both decreased DFS and OS (p < 0.05). There was strong correlation between angiopoietin and VEGF pathway genes. While high expression of VEGFA alone was not associated with survival, high co-expression with Ang2 was associated with decreased OS. CONCLUSIONS: This study validates TCGA as a representative database providing genomic data and survival outcomes in breast cancer. Our TCGA data support the angiopoietin pathway as a key mediator in the pathologic angiogenic switch in breast cancer.
Entities:
Keywords:
ANGPT; Angiogenesis; Genomic; Outcomes; TCGA; TEK; The Cancer Genome Atlas
Authors: Yihai Cao; Jack Arbiser; Robert J D'Amato; Patricia A D'Amore; Donald E Ingber; Robert Kerbel; Michael Klagsbrun; Sharon Lim; Marsha A Moses; Bruce Zetter; Harold Dvorak; Robert Langer Journal: Sci Transl Med Date: 2011-12-21 Impact factor: 17.956
Authors: Kathy D Miller; Linnea I Chap; Frankie A Holmes; Melody A Cobleigh; P Kelly Marcom; Louis Fehrenbacher; Maura Dickler; Beth A Overmoyer; James D Reimann; Amy P Sing; Virginia Langmuir; Hope S Rugo Journal: J Clin Oncol Date: 2005-02-01 Impact factor: 44.544
Authors: Sandra P D' Angelo; Michelle R Mahoney; Brian A Van Tine; Douglas R Adkins; Maria T Grosse Perdekamp; Mercedes M Condy; Jason J Luke; Eliza Woodward Hartley; Cristina R Antonescu; William D Tap; Gary K Schwartz Journal: Cancer Chemother Pharmacol Date: 2015-02-12 Impact factor: 3.333
Authors: O Coutelle; L M Schiffmann; M Liwschitz; M Brunold; V Goede; M Hallek; H Kashkar; U T Hacker Journal: Br J Cancer Date: 2015-01-06 Impact factor: 7.640
Authors: Tstutomu Kawaguchi; Li Yan; Qianya Qi; Xuan Peng; Stephen B Edge; Jessica Young; Song Yao; Song Liu; Eigo Otsuji; Kazuaki Takabe Journal: Ann Surg Oncol Date: 2018-10-11 Impact factor: 5.344
Authors: Sergei A Koshkin; Olga V Anatskaya; Alexander E Vinogradov; Vladimir N Uversky; Guy W Dayhoff; Margarita A Bystriakova; Valery A Pospelov; Elena N Tolkunova Journal: Int J Mol Sci Date: 2021-04-28 Impact factor: 5.923